Pasar al contenido principal

RED PATOLOGICA INTEGRAL COMO ESTRATEGIA MULTIDIANA PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER.

PID2021-123481OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

KEAP1-NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential

  • Crisman, Enrique
  • Duarte, Pablo
  • Dauden, Esteban
  • Cuadrado, Antonio
  • Rodríguez-Franco, María Isabel
  • López, Manuela G.
  • León, Rafael
The transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) is considered the master regulator of the phase II antioxidant response. It controls a plethora of cytoprotective genes related to oxidative stress, inflammation, and protein homeostasis, among other processes. Activation of these pathways has been described in numerous pathologies including cancer, cardiovascular, respiratory, renal, digestive, metabolic, autoimmune, and neurodegenerative diseases. Considering the increasing interest of discovering novel NRF2 activators due to its clinical application, initial efforts were devoted to the development of electrophilic drugs able to induce NRF2 nuclear accumulation by targeting its natural repressor protein Kelch-like ECH-associated protein 1 (KEAP1) through covalent modifications on cysteine residues. However, off-target effects of these drugs prompted the development of an innovative strategy, the search of KEAP1-NRF2 protein–protein interaction (PPI) inhibitors. These innovative activators are proposed to target NRF2 in a more selective way, leading to potentially improved drugs with the application for a variety of diseases that are currently under investigation. In this review, we summarize known KEAP1-NRF2 PPI inhibitors to date and the bases of their design highlighting the most important features of their respective interactions. We also discuss the preclinical pharmacological properties described for the most promising compounds., Enrique Crisman is the recipient of a PFIS fellowship of ISCIII. Pablo Duarte is the recipient of an FPU fellowship of the Spanish Ministry of education. Authors gratefully acknowledge funding from IS Carlos III, Comunidad de Madrid, and Spanish Research Agency. We thank Fundación Teófilo Hernando for its continued support. All schemes were created with Biorender.com. IS Carlos III cofinanced by the European Regional Development funds (FEDER) grant number PI17/01700. General Council for Research and Innovation of the Community of Madrid and European Structural Funds (grant B2017/BMD‐3827 NRF24ADCM. Spanish Ministry of Science, Innovation and Universities (grants PID2021‐123481OB‐I00, PID2021‐122650OB‐I00, PID2021‐125986OB‐I00, PDC2021‐121421‐I00, and PID2019‐110061RB‐I00). The authors have no financial support to disclose., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discovery of a potent melatonin-based inhibitor of quinone reductase-2 with neuroprotective and neurogenic properties

  • Herrera-Arozamena, Clara
  • Estrada-Valencia, Martín
  • García-Díez, Guillermo
  • Pérez, Concepción
  • León, Rafael
  • Infantes, Lourdes
  • Morales-García, José A.
  • Pérez-Castillo, Ana
  • Sastre, Eric del
  • López, Manuela G.
  • Rodríguez-Franco, María Isabel
5-Methoxy-3-(5-methoxyindolin-2-yl)-1H-indole (3), whose structure was unambiguously elucidated by X-ray analysis, was identified as a multi-target compound with potential application in neurodegenerative diseases. It is a low nanomolar inhibitor of QR2 (IC50 = 7.7 nM), with greater potency than melatonin and comparable efficacy to the most potent QR2 inhibitors described to date. Molecular docking studies revealed the potential binding mode of 3 to QR2, which explains its superior potency compared to melatonin. Furthermore, compound 3 inhibits hMAO-A, hMAO-B and hLOX-5 in the low micromolar range and is an excellent ROS scavenger. In phenotypic assays, compound 3 showed neuroprotective activity in a cellular model of oxidative stress damage, it was non-toxic, and was able to activate neurogenesis from neural stem-cell niches of adult mice. These excellent biological properties, together with its both good in silico and in vitro drug-like profile, highlight compound 3 as a promising drug candidate for neurodegenerative diseases., Theauthors gratefully acknowledge the following financial supports: Spanish Ministry of Science, Innovation and Universities; Spanish Research Agency; and European Regional Development Funds (grants PID2021-122650OB-I00 to M.I.R.-F.; PDC2022-133809-I00 to M.G.L., R.L., and M.I.R.-F.; PID2021-123481OB-I00 to R.L.; PID2021125986OB-I00 to M.G.L.; PID2020-117400 GB-I00 to L.I.); General Council for Research and Innovation of the Community of Madrid (grant P2022/BMD-7230 to M.G.L., R.L., and M.I.R.-F.); Spanish National Research Council (CSIC, grant PIE-202480E175 to M.I.R.-F.) Compound 3 X-ray experiments were performed at BL13-XALOC beamline at ALBA Synchrotron with the collaboration of ALBA staff. We thank the Spanish Ministry of Science, Innovation and Universities for the fellowships FPU22/03672 to G.G.-D. and FPU18/00630 to E.dS. The authors acknowledge the support of the European COST Action CA20121 (BenBedPhar) and the Fundación Teófilo Hernando, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Network-Based Drug Optimization toward the Treatment of Parkinson’s Disease: NRF2, MAO-B, Oxidative Stress, and Chronic Neuroinflammation

  • Duarte, Pablo
  • Sanchez-Porro, Francisco J.
  • Crisman, Enrique
  • Cores, Ángel
  • Jiménez, Irene
  • Cuadrado, Antonio
  • Menéndez, J. Carlos
  • León, Rafael
Parkinson’s disease (PD), the second most common neurodegenerative disorder, affects around 10 million people worldwide. It is a multifactorial disease marked by dopaminergic neuron loss with oxidative stress (OS) and neuroinflammation as key pathological drivers. Current treatments focus on dopamine replacement and are symptomatic, underscoring the urgent need for disease-modifying therapies. Here, we present a novel class of dual MAO-B inhibitors and NRF2 inducers with neuroprotective properties in in vitro PD models. Through an optimization program, we enhanced their MAO-B inhibitory potency, selectivity, and NRF2 induction capacity while achieving favorable pharmacokinetic profiles. Virtual library screening identified two core derivatives, leading to the development of compound 11, which exhibited potent anti-inflammatory and neuroprotective activity in OS-related in vitro models. Compound 11 also demonstrated high liver microsomal stability and favorable pharmacokinetics in mice, making it a promising candidate for further investigation as a potential PD therapy., We are grateful for financial support from the Spanish Ministry of Health (Instituto de Salud Carlos III) (grant PI17/001700 and PI20/00433), the Spanish Ministry of Science (grant PID2021-123481OB-I00 to RL and PID2021-124983OB-I00) to JCM), and Comunidad de Madrid (grant P2022/BMD-7230-CAM-22 to RL). P.D. and F.J.S. thank MEC for FPU fellowships and E.C. thanks ISCIII for PFIS fellowship. The authors acknowledge the support from the European COST Action CA20121: Bench to bedside transition for the pharmacological regulation of NRF2 in noncommunicable diseases (BenBedPhar). Webpage: https://benbedphar.org/ about-benbedphar. The authors acknowledge technical support from Tomas Robredo with liver microsome experiments. We would also like to thank “Fundación Teófilo Hernando” for its continued support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Potent Nrf2-Inducing C6-Isothiocyanate Glucose Derivatives with Dual Antioxidant and Antitumor Activity

  • Prieto Ramírez, Luis Alberto
  • Khiar-Fernández, Nora
  • Calderón-Ruiz, R.
  • Giraud, Emelyne
  • Calderón-Montaño, José Manuel
  • Lucia-Tamudo, Jesús
  • León, Rafael
  • Pérez-Simón, José A.
  • López-Lázaro, Miguel
  • Recio, Rocío
  • Torre-Madrid, Elena de la
  • Valdivia, Victoria
  • Fernández, Inmaculada
This article belongs to the Section Natural and Synthetic Antioxidants., Isothiocyanates (ITCs) are well-known electrophilic agents with antioxidant and anticancer properties, largely attributed to their ability to activate the Nrf2/ARE pathway. Building on previous work with C1-ITC glycosyl derivatives, we designed and synthesized a new series of S-glycosyl isothiocyanates in which the ITC group was repositioned to the C6 carbon of the glucose scaffold. This structural rearrangement yielded stable and synthetically accessible derivatives with markedly enhanced biological profiles. Several compounds showed potent Nrf2 activation at non-cytotoxic concentrations, with CD values comparable to or exceeding those of natural ITCs. In parallel, the new C6-ITC derivatives displayed significant antiproliferative activity against leukemia and solid tumor cell lines. Among them, the phenylsulfone derivative 13 emerged as a particularly promising dual-action molecule, combining strong Nrf2 induction with low-micromolar cytotoxicity. Molecular docking was used as a hypothesis-generating approach and suggested a possible interaction with the STAT3 SH2 domain, although further studies are needed to validate this target. Overall, these results support glucose-based ITCs as a versatile platform for the development of multifunctional antioxidants with complementary anticancer properties., This publication is part of the project PID2022-138863OB-I00, funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU., This work is part of the projects: PID2022-138863OB-I00, funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU (to I.F.); PID2021-123481OB-I00 and PID2024-157469OB-I00 (to R.L.) and P2022/BMD-7230-CAM-22 (to R.L.). The US (University of Seville) is also acknowledged for the support provided through its own research plan (VII PPIT-US). We gratefully thank the Centre of Research Technology and Innovation of the University of Seville (CITIUS) for NMR facilities. During the preparation of this work, the author(s) used Gemini and ChatGPT 5.2 in order to optimize the semantic coherence of the sentences and ensure their grammatical and stylistic accuracy in the English language, thereby guaranteeing the utmost clarity and precision in the ex-pression of the intended ideas. After using this tool/service, the authors reviewed and edited the content as needed and takes full responsibility for the content of the published article., Peer reviewed